Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novartis wins FDA fast track designation for investigational osteoarthritis drug

By Brian Buntz | September 3, 2021

NovartisNovartis (NYSE:NVS) has received FDA fast track designation for LNA043, a potential treatment for osteoarthritis of the knee.

LNA043 is a modified version of the human angiopoietin-like 3 (ANGPTL3). The drug would be a potential first-in-class disease-modifying osteoarthritis therapy.

Osteoarthritis is a common joint disorder. In 2017, more than 300 million people internationally had either hip or knee osteoarthritis, according to an article in the Annals of the Rheumatic Diseases.  

At present, drugs play a supporting role in treating osteoarthritis. Patients primarily use them to reduce pain and swelling.

Several organizations, including Merck (NYSE:MRK), Novartis and a number of smaller companies, have launched clinical trials to test various investigational disease-modifying therapies for the condition.

LNA043 is an angiopoietin-like 3 (ANGPTL3) agonist targeting damaged cartilage. In a proof-of-concept study, the drug regenerated damaged cartilage when injected into the knee joint.

The Novartis Institutes for BioMedical Research discovered the drug LNA043.

The company has also completed a Phase 1 trial for M6495, an investigational osteoarthritis treatment. M6495 is an ADAMTS-5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) inhibitor.


Filed Under: clinical trials, Drug Discovery
Tagged With: fast track designation, FDA, LNA043, Novartis
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50